The therapeutic role of 5-HT1A and 5-HT2A receptors in depression

Journal of Psychiatry and Neuroscience

Volumn 29, Issue 4, 2004, Pages 252-265

  Celada, Pau ^a   Puig, M Victoria ^a   Amargós Bosch, Mercè ^a   Adell, Albert ^a   Artigas, Francesc ^a  

^a INST D INVESTIGACIONS B   (Spain)

Author keywords

Antidepressive agents; Depression; Dorsal raphe nucleus; Gamma aminobutyric acid; Medial prefrontal cortex; Microdialysis; Pindolol; Receptors, AMPA; Serotonin; Serotonin uptake inhibitors

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; FLUOXETINE; IPSAPIRONE; LYSERGIDE; MIANSERIN; MIRTAZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEFAZODONE; PINDOLOL; REPINOTAN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNCLASSIFIED DRUG;

BRAIN CORTEX; BRAIN FUNCTION; BRAIN NERVE CELL; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG UTILIZATION; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; MAJOR DEPRESSION; NEGATIVE FEEDBACK; NEOCORTEX; NERVE CONDUCTION; NERVE FIBER; NERVE TRACT; NEUROCHEMISTRY; NONHUMAN; POSTSYNAPTIC MEMBRANE; PREFRONTAL CORTEX; PRESCRIPTION; PRESYNAPTIC NERVE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PYRAMIDAL NERVE CELL; RECEPTOR BLOCKING; SEROTONIN UPTAKE;

AUTORECEPTORS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PINDOLOL; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 4444260616     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (109)

1. Murray CGL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
2. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-8.
3. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
4. 1A receptors. J Neurosci 1998;18:10150-6.
5. 1A agonists in the treatment of depression? Biol Psychiatry 2003;53:93-103.
6. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34:13-25.
7. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992;72:165-229.
8. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-6.
9. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-152.
10. Adell A, Celada P, Abellán MT, Artigas F. Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Rev 2002;39:154-80.
11. Oleskevich S, Descarries L. Quantified distribution of the serotonin innervation in adult rat hippocampus. Neuroscience 1990;34:19-33.
12. Beaudet A, Descarries L. The monoamine innervation of rat cerebral cortex: synaptic and nonsynaptic axon terminals. Neuroscience 1978;3:851-60.
13. 1B agonists. Synapse 1987;1:3-9.
14. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987;1:470-80.
15. Adell A, Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 1991;343:237-44.
16. 1A antagonists. Trends Neurosci 1996;19:378-83.
17. 1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br J Pharmacol 1997;122:733-41.
18. Casanovas JM, Berton O, Celada P, Artigas F. In vivo actions of the selective 5-HT1A receptor agonist BAY x 3702 on serotonergic cell firing and release. Naunyn Schmiedebergs Arch Pharmacol 2000;362:248-54.
19. 1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem 2001;79:172-82.
20. Araneda R, Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991;40:399-412.
21. Tanaka E, North RA. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol 1993;69:1749-57.
22. Ashby CR, Edwards E, Wang RY. Electrophysiological evidence for a functional interaction between 5-HT(1A) and 5-HT(2A) receptors in the rat medial prefrontal cortex: an ion-tophoretic study. Synapse 1994;17:173-81.
23. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992;229:101-3.
24. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentration of serotonin in the dorsal raphe prevents the drug's effect in frontal cortex. Brain Res 1992;584:322-4.
25. Malagié I, Trillat AC, Jacquot C, Gardier AM. Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur J Pharmacol 1995;286:213-7.
26. Hervás I, Artigas F. Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors. Eur J Pharmacol 1998;358:9-18.
27. Quinaux N, Scuvée-Moreau J, Dresse A. Inhibition of in vitro and ex vivo uptake of noradrenaline and 5-hydroxytryptamine by five antidepressants; correlation with reduction of spontaneous firing rate of central monoaminergic neurones. Naunyn Schmiedebergs Arch Pharmacol 1982;319:66-70.
28. Rollema H, Clarke T, Sprouse JS, Schulz DW. Combined administration of a 5-hydroxytryptamine (5-HT)(1D) antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J Neurochem 1996;67:2204-7.
29. Hervás I, Queiroz CM, Adell A, Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br J Pharmacol 2000;130:160-6.
30. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15:243-5.
31. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 1993;14:262.
32. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51.
33. Artigas F, Celada P, Laruelle M, Adell A. How does pindolol improve antidepressant action? Trends Pharmacol Sci 2001;22:224-8.
34. Rasanen P, Hakko H, Tiihonen J. Pindolol and major affective disorders: a three-year follow-up study of 30,485 patients. J Clin Psychopharmacol 1999;19:297-302.
35. Pérez V, Puigdemont D, Gilaberte I, Alvarez E, Artigas F. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 2001;21:36-45.
36. Raurich A, Mengod G, Artigas F, Cortés R. Displacement of the binding of 5-HT(1A) receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain. Synapse 1999;34:68-76.
37. 1A receptors in human and rat brain. J Neurochem 2000;75:755-62.
38. Martinez D, Hwang D, Mawlawi O, Slifstein M, Kent J, Simpson N, et al. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 2001;24:209-29.
39. Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, Koepp MJ, et al. Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology 2000;23:285-93.
40. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 1996;15:349-60.
41. 1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats. J Pharmacol Exp Ther 1999;288:843-8.
42. 1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl] butyl]-1, 2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4- (2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther 2002;301:1144-50.
43. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256-9.
44. Marangell LB, Johnson CR, Kertz B, Zboyan HA, Martinez JM. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry 2002;63:391-5.
45. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
46. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51:183-8.
47. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 2003;28:402-12.
48. 2A receptors by agonists and antagonists. Brain Res Bull 2001;56:441-51.
49. 2A antagonist (M100907) and the SSRI fluoxetine on DRL 72-s behavior. Abstr Soc Neurosci 2001;27:975-8.
50. Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989;46:243-50.
51. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001;11:240-9.
52. Robinson RG, Kubos KL, Starr LB, Rao K, Price TR. Mood disorders in stroke patients. Importance of location of lesion. Brain 1984;107:81-93.
53. Fuster JM. The prefrontal cortex. Anatomy, physiology and neuropsychology of the frontal lobe. Philadelphia: Lipincott-Raven; 1997.
54. Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 2001;24:167-202.
55. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997;27:79-82.
56. Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine(2A) serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A 1998;95:735-40.
57. 3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 2000;417:337-48.
58. Jansson A, Tinner B, Bancila M, Verge D, Steinbusch HW, Agnati LF, et al. Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain. J Chem Neuroanat 2001;22:185-203.
59. Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G, et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 2001;21:9856-66.
60. Kroeze WK, Roth BL. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol Psychiatry 1998;44:1128-42.
61. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21:S106-15.
62. Groenewegen HJ, Uylings HB. The prefrontal cortex and the integration of sensory, limbic and autonomic information. Prog Brain Res 2000;126:3-28.
63. Murase S, Grenhoff J, Chouvet G, Gonon FG, Svensson TH. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 1993;157:53-6.
64. Shim SS, Bunney BS, Shi WX. Effects of lesions in the medial prefrontal cortex on the activity of midbrain dopamine neurons. Neuropsychopharmacology 1996;15:437-41.
65. Jodo E, Chiang C, Aston-Jones G. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience 1998;83:63-79.
66. Hajos M, Richards CD, Szekely AD, Sharp T. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience 1998;87:95-108.
67. Celada P, Puig MV, Casanovas JM, Guillazo G, Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 2001;21:9917-29.
68. Aghajanian GK, Wang RY. Habenular and other midbrain raphe afferents demonstrated by a modified retrograde tracing technique. Brain Res 1977;122:229-42.
69. Sesack SR, Deutch AY, Roth RH, Bunney BS. Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol 1989;290:213-42.
70. Takagishi M, Chiba T. Efferent projections of the infralimbic (area 25) region of the medial prefrontal cortex in the rat: an anterograde tracer PHA-L study. Brain Res 1991;566:26-39.
71. Peyron C, Petit JM, Rampon C, Jouvet M, Luppi PH. Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 1998;82:443-68.
72. Varga V, Szekely AD, Csillag A, Sharp T, Hajos M. Evidence for a role of GABA interneurones in the cortical modulation of midbrain 5-hydroxytryptamine neurones. Neuroscience 2001;106:783-92.
73. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978;179:641-68.
74. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 1985;346:205-30.
75. 2 receptors and serotonergic axons in rat neocortex. Brain Res 1988;453:315-28.
76. 1A receptor in the rat brain: correlation with receptor binding. J Neurosci 1992;12:440-53.
77. 2C receptors. Mol Brain Res 1994;23:163-78.
78. 2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology 2000;148:400-43.
79. 2A receptors in working memory. J Neurosci 2002;22:2843-54.
80. 1A receptor mutant mice. Proc Natl Acad Sci U S A 1998;95:15049-54.
81. 1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 2000;39:547-52.
82. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin(1A) receptor. Proc Natl Acad Sci U S A 1998;95:10734-9.
83. Arango V, Underwood MD, Mann JJ. Postmortem findings in suicide victims. Implications for in vivo imaging studies. Ann N Y Acad Sci 1997;836:269-87.
84. 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57:174-80.
85. Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C. Altered editing of serotonin-2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002;34:349-56.
86. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:1521-31.
87. Kia HK, Miquel MC, Brisorgueil MJ, Daval G, Riad M, El Mestikawy S, et al. Immunocytochemical localization of serotonin(1A) receptors in the rat central nervous system. J Comp Neurol 1996;365:289-305.
88. De Felipe J, Arellano JI, Gomez A, Azmitia EC, Muñoz A. Pyramidal cell axons show a local specialization for GABA and 5-HT inputs in monkey and human cerebral cortex. J Comp Neurol 2001;433:148-55.
89. Miner LA, Backstrom JR, Sanders-Bush E, Sesack SR. Ultrastructural localization of serotonin(2A) receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 2003;116:107-17.
90. 2+/calmodulin- dependent kinase II in prefrontal cortical pyramidal neurons. J Biol Chem 2002;277:36553-62.
91. Ashby CR, Jiang LH, Kasser RJ, Wang RY. Electrophysiological characterization of 5-hydroxytryptamine-2 receptors in the rat medial prefrontal cortex. J Pharmacol Exp Ther 1990;252:171-8.
92. Aghajanian GK, Marek GJ. Serotonin induces excitatory post-synaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997;36:589-99.
93. 2A receptors, increases EPSCs in layer v pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 1999;825:161-71.
94. Arvanov VL, Liang XF, Magro P, Roberts R, Wang RY. A pre-and postsynaptic modulatory action of 5-HT and the 5-HT2A(2C) receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci 1999;11:2917-34.
95. Zhou FM, Hablitz JJ. Activation of Serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol 1999;82:2989-99.
96. 2A receptors. Relationship to thalamocortical afferents. Cereb Cortex 2003;13:870-82.
97. Marek GJ, Wright RA, Gewitz JC, Schoepp DD. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in neocortex. Neuroscience 2001;105:379-92.
98. 2C receptors in CHO-K1 cells. Br J Pharmacol 1999;128:13-20.
99. 3 receptors in the medial prefrontal cortex: a microiontophoretic study. Eur J Pharmacol 1989;173:193-6.
100. Newberry NR, Footitt DR, Papanastassiou V, Reynolds DJ. Actions of 5-HT on human neocortical neurones in vitro. Brain Res 1999;833:93-100.
101. 2A receptor antagonist, directly activates post-synaptic 5-HT inhibitory responses in the rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol 1995;352:283-90.
102. Gartside SE, Hajós-Korcsok E, Bagdy E, Harsing LG Jr, Sharp T, Hajós M. Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience 2000;98:295-300.
103. Puig MK, Artigas F, Celada P. Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex. In press.
104. 2A receptors in prefrontal cortex. Cereb Cortex 2004;14:281-99.
105. Andrade R, Malenka RC, Nicoll RA. A G protein couples serotonin and GABA B receptors to the same channel in hippocampus. Science 1986;234:1261-5.
106. Gozlan H, Laporte AM, Thibault S, Schechter LE, Bolaños- Jiménez F, Hamon M. Differential effects of N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain. Neuropharmacology 1994;33;423-31.
107. Carr DB, Sesack SR. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 2000;20:3864-73.
108. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996;93:9235-40.
109. 2 receptors in rat brain: an autoradiographic study. Synapse 1993;14:324-31.